HKSE - Delayed Quote HKD
JUNSHI BIO (1877.HK)
15.420
-0.560
(-3.50%)
At close: April 25 at 4:08:21 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jun Xiong | Executive Chairman | -- | -- | 1974 |
| Mr. Cong Li | Co-CEO & Executive Director | -- | -- | 1964 |
| Dr. Jianjun Zou M.D., Ph.D. | GM, CEO & Executive Director | -- | -- | 1971 |
| Dr. Ning Li M.D., Ph.D. | Executive Vice-Chairman of the Board | -- | -- | 1961 |
| Mr. Baohong Xu | Chief Financial Officer | -- | -- | 1979 |
| Mr. Zhuobing Zhang | Deputy GM & Executive Director | -- | -- | 1967 |
| Dr. Sheng Yao Ph.D. | Deputy GM, Senior VP & Executive Director | -- | -- | 1975 |
| Dr. Gang Wang | Deputy GM, Chief Quality Officer, Senior VP of Industry Affairs & Executive Director | -- | -- | 1957 |
| Dr. Xin Li | Senior VP of Government Affairs & Executive Director | -- | -- | 1979 |
| Mr. Zhengyu Wang | Joint Company Secretary | -- | -- | 1995 |
JUNSHI BIO
Building 7, No. 6
Floor 16 Lane 100, Pingjiaqiao Road Pudong New District
Shanghai, 200126
China
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,578
Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Corporate Governance
JUNSHI BIO’s ISS Governance QualityScore as of April 1, 2025 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 7; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 27, 2025 at 10:59 AM UTC
JUNSHI BIO Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
9966.HK Alphamab Oncology
6.910
-0.43%
6978.HK Immunotech Biopharm Ltd
4.150
+1.97%
1873.HK VIVA BIOTECH
1.480
-1.99%
9688.HK Zai Lab Limited
25.650
-1.16%
6660.HK AIM Vaccine Co., Ltd.
3.290
-2.95%
9969.HK InnoCare Pharma Limited
10.140
-3.61%
2162.HK Keymed Biosciences Inc.
42.250
-6.11%
2157.HK Lepu Biopharma Co., Ltd.
4.350
-3.97%
2137.HK Brii Biosciences Limited
2.000
+8.11%
1952.HK Everest Medicines Limited
47.400
+2.16%